Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAP4343 add-on therapy in treatment-resistant major depressive episode (Phase 2)
2018-002901-68Phase 2Completed
- Sponsor
- Mapreg
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing MAP4343 add-on with Placebo add-on (2 arms). Started Aug 2018; status: completed.
02
Drugs
MAP4343
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-002901-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002901-68.